COMPANY PROFILE / CELL CULTURE TECHNOLOGY
Sartorius
A German specialist that earns 80% of its revenue from bioprocessing, has bought up media raw materials and is betting on automated cell therapy manufacturing
Sartorius, headquartered in Göttingen, Germany, makes the equipment and consumables used to manufacture biopharmaceuticals. Of its 2025 revenue of €3,538.1 million, 81% came from the Bioprocess Solutions division. With the businesses that touch cell culture making up most of the company, it is close to being a bioprocessing pure play. In 2022 and 2023 it bought, in quick succession, a maker of recombinant albumin (Albumedix) and a maker of transfection reagents (Polyplus, about €2.4 billion), both used in cell and gene therapy, and in March 2026 it unveiled Eveo, a platform that automates and parallelises the manufacture of CAR-T and other cell therapies. This profile keeps the company as a whole to a minimum and concentrates on what Sartorius is putting into cell culture, who it is working with and what it is aiming for.
- Sartorius in 30 seconds, and where it stands in cell culture
- The logo and how the name is written
- Where the company sits in the cell culture field
- Scale (focusing on the Bioprocess Solutions division)
- Resources committed to cell culture
- What it has done so far
- What comes next
- What the company is aiming for in cell culture
- Map of cell culture partnerships
- Technologies, products and services
- The risks this company carries
- Glossary, references and claim-to-source audit
1. Sartorius in 30 seconds, and where it stands in cell culture
(ordinary and preference shares)A member of the MDAX and TecDAX. Subsidiary Sartorius Stedim Biotech is listed on Euronext Paris
about €2.4 billionCompleted July 2023. Transfection reagents for viral vectors
Companies involved in cell culture fall into three broad types: contract development and manufacturing organisations (CDMOs), suppliers of tools, consumables and media, and developers of cell and regenerative therapies. Sartorius is a supplier. The annual report says the Bioprocess Solutions division "serves pharmaceutical and biotechnology companies, as well as contract manufacturers", and that its portfolio "includes cell lines, cell culture media and reagents, bioreactors, a variety of technologies for the separation, purification, and concentration" of biological products, along with solutions for storage and transport Sourced. It says nothing about manufacturing drugs under contract itself, and even for its new cell therapy system it works with a CDMO as its pilot partner. Of the two meanings of "cell culture" (1) growing animal cells to produce antibodies and other biologics and (2) cell therapy, where the cells themselves are the product, it sells into both. What sets it apart is that, beyond bioreactors and bags, it has used acquisitions to gather up "raw materials" such as the albumin and cytokines added to media, and transfection reagents.
2. The logo and how the name is written
The Sartorius logo is a trademark of the company. We have not recreated it with generated imagery;
the file img/sartorius_logo.svg is an image taken from the company's official website.
A note on names: the listed parent company is Sartorius AG (Germany), and much of the bioprocess business is run by its Paris-listed subsidiary Sartorius Stedim Biotech S.A. (Aubagne, France). At the end of 2025 Sartorius AG held 71.5% of that company's shares. The Polyplus and Albumedix acquisitions were also made through the subsidiary; the Polyplus announcement, for example, describes Sartorius acting "through its French listed subgroup Sartorius Stedim Biotech". This article uses "Sartorius" for the group and names "Sartorius Stedim Biotech" explicitly when referring to the subsidiary.
https://www.sartorius.com/en3. Where the company sits in the cell culture field
The annual report names "certain business units of Danaher Corporation, Merck KGaA, and Thermo Fisher Scientific Inc." as the Bioprocess Solutions division's principal competitors Sourced. It does not say which business units, but the line-up matches Cytiva (part of Danaher), Merck and Thermo Fisher, which this series places in the same category.
4. Scale (focusing on the Bioprocess Solutions division)
| Group as a whole | 2023 | 2024 | 2025 |
|---|---|---|---|
| Sales revenue (€ million) | 3,395.7 | 3,380.7 | 3,538.1 |
| R&D costs (expensed, € million) | - | 196.8 | 174.0 |
| Capital expenditure (€ million) / ratio to sales | - / 16.5% | 409.9 / 12.1% | 441.9 / 12.5% |
| Employees (31 December) | 14,614 | 13,528 | 14,042 |
| Bioprocess Solutions division (€ million) | 2022 | 2023 | 2024 | 2025 | Jan to Jun 2026 |
|---|---|---|---|---|---|
| Sales revenue | 3,326.5 | 2,678.2 | 2,690.2 | 2,865.0 | 1,475.5 (prior-year period 1,434.9) |
| Underlying EBITDA | 1,188.4 | 782.3 | 787.2 | 907.0 | - |
| Underlying EBITDA margin | 35.7% | 29.2% | 29.3% | 31.7% | - |
| Employees | - | - | 10,487 | 10,878 | - |
Sources: Annual Report 2025 (key figures, divisional results, employees) and Half-Year Report 2026. R&D costs are group-wide figures; no divisional breakdown is disclosed.
Bioprocess Solutions revenue rose 6.5% in 2025 (9.5% in constant currencies), and by region it came about 42% from EMEA, about 36% from the Americas and about 22% from Asia-Pacific Sourced. The report puts the growth down chiefly to recurring demand for consumables for biopharmaceutical production, noting that the prior-year basis "had still been partially impacted by the reduction of elevated customer inventories", while business with equipment and systems "continued to decline due to ongoing industry-wide investment restraint, but showed increasing stabilization" Sourced. In January to June 2026 revenue rose 6.7% in constant currencies (8.3% excluding the expected refunds to customers arising from U.S. tariff reimbursements).
What should not be missed is that divisional revenue fell by about 19.5% between 2022 and 2023 Our calculation (3,326.5 to 2,678.2). 2025 revenue has still not returned to its 2022 level. The figures show how sharply a cell culture supplier's results can swing with customers' inventory and investment cycles.
Revenue from media alone, or from cell therapy products alone, is not disclosed within the division Not yet confirmed. All the annual report gives is the composition: "recurring business with sterile single-use products accounts for just above three-quarters of the division's sales revenue". The annual report also quotes a research firm's (SDi's) estimate of the laboratory instruments market, but this article does not use market size estimates.
5. Resources committed to cell culture
| Resource | What primary sources confirm | Status |
|---|---|---|
| People | 10,878 employees in the Bioprocess Solutions division (end of 2025). About 140 people at the Freiburg site that makes cell and gene therapy components (with room for up to 180) | Confirmed (headcount dedicated to cell therapy not disclosed) |
| Money (capital expenditure) | Group capital expenditure of €441.9 million (2025). More than €140 million for the new Freiburg site for cell and gene therapy components. A GMP plant for transfection reagents in Illkirch, France. A powder media plant in Yauco, Puerto Rico (2023). The largest project is a sterile consumables plant in Songdo, South Korea | Confirmed (capital expenditure by division not disclosed) |
| Money (R&D) | For the group, €174.0 million expensed and €282.5 million in total including capitalised costs (2025) | Confirmed for the group. Not disclosed by division |
| Investments and acquisitions | Polyplus (about €2.4 billion, 2023), Albumedix (about £415 million, 2022), CellGenix (majority acquired in 2021, fully integrated in early 2026), MatTek (US$80 million, 2025), a stake of about 10.1% in BICO (about €45 million, 2022) and a minority stake in Nanotein Technologies (up to US$3 million, 2025) | Confirmed |
| Universities and research institutions | A bioprocess automation lab at McMaster University in Canada (January 2025). A training centre for continuous manufacturing with Ireland's NIBRT (National Institute for Bioprocessing Research and Training), announced in September 2026. CellGenix was founded at the Freiburg University Medical Center | Confirmed |
In money terms the largest item is the Polyplus acquisition (about €2.4 billion), equivalent to about 80% of the Bioprocess Solutions division's 2025 revenue Our calculation. Polyplus makes transfection reagents and plasmid DNA, supplying materials that are essential to viral vector manufacturing Sourced.
The annual report says there is "a high vertical integration" for its top-selling product groups. Sartorius produces its filters and single-use bags from supplied materials such as cellulose, polymers and plastic films, and also makes the electronics, sensors, control software and connectors for its bioprocess equipment in house; stainless steel components and housings are procured from contract manufacturers Sourced. It also says that Aubagne in France, the main site for single-use bags, has obtained ISCC PLUS certification, allowing it to make plastic components from certified renewable raw materials.
The wetted film of a culture bag is an "invisible raw material" that touches the cells. Substances leaching from the film can hinder cell growth, and changing the resin grade or additives means re-evaluation. Having film processing and bag manufacturing in house means controlling both quality and supply yourself, which is as important as quality control of the media Not yet confirmed. The annual report does not disclose which resins are used or in what layer structure.
6. What it has done so far
| When | What happened | Why it matters |
|---|---|---|
| 2021 | Acquires a majority stake in CellGenix (Freiburg, Germany), a maker of cytokines, growth factors and other components used in cell therapy manufacturing | Brings "raw materials added to media" for cell therapy in house |
| August to September 2022 | Acquires Albumedix (Nottingham, UK) for about £415 million, a maker of recombinant human albumin | Secures a raw material that replaces animal-derived components in media |
| December 2022 | Strategic partnership with BICO of Sweden, taking a stake of about 10.1%. Joint research on 3D cell printing and digitalising cell line development | The field of cell models for research |
| July 2023 | Completes the acquisition of Polyplus (Strasbourg, France) (about €2.4 billion, about 270 employees). The same month, opens a powder media plant (21,500 square feet) in Yauco, Puerto Rico | Transfection reagents for viral vectors, and media supply for the Americas |
| January 2025 | Opens a bioprocess automation lab at McMaster University | Joint development and training with a university |
| July 2025 | Completes the acquisition of MatTek (U.S., 3D microtissue models) for US$80 million. It joins the Lab Products & Services division | Cell models for drug discovery research. A separate field from cell culture for production |
| August 2025 | Partners with and takes a minority stake in Nanotein Technologies (U.S.). Gains exclusive worldwide distribution of its T cell and NK cell activation reagents | Reagents for the "first step of culture" in cell therapy |
| September 2025 | Expands the transfection reagent plant in Illkirch, France to GMP standard (more than 8,000 square metres) | Turns the Polyplus acquisition into production capacity |
| March 2026 | Unveils Eveo, an automated manufacturing platform for cell therapy. Says a pilot with the CDMO ElevateBio confirmed performance in line with design expectations. Announces mid-term targets the same month | From supplier of components to supplier of the entire manufacturing system |
| May 2026 | Opens a new site for cell and gene therapy components in Freiburg (more than €140 million, more than doubling capacity) | Supply capacity for cytokines and growth factors |
| September 2026 | Partners with Ireland's NIBRT to set up a training centre for continuous manufacturing (starting October to December 2026) | Spreads continuous manufacturing technology across the industry |
7. What comes next
in constant currenciesUnderlying EBITDA margin expected slightly above 32%. Forecast confirmed in the half-year report
of 9% to 12% a yearIn constant currencies. EBITDA margin expected to improve by 60 to 85 basis points a year
First deliveries in 2027ElevateBio, as a preferred partner, gets access to one of the first systems
The March 2026 release on the mid-term targets lists the "emerging businesses" it plans to develop as advanced therapy solutions, advanced cell models, process analytical technologies, and analytical characterization and quality control platforms Sourced. The same release gives the company's own view of market growth (its addressable markets growing by approximately 7 to 9 percent a year), but this is the company's assumption, not an actual result Not yet confirmed.
None of the following appears in the annual report, half-year report or releases we read Not yet confirmed.
Eveo's price or order targets; revenue from products for cell and gene therapy; Polyplus's revenue since the acquisition; media production capacity (in tonnes or similar); and the price paid for CellGenix. The claim that Eveo cuts manufacturing costs by "around 90 percent" is based on the company's financial modelling, not on results at actual customers.
8. What the company is aiming for in cell culture
This section goes beyond what the company says directly. It sets out inferences that can be drawn from primary sources, each with its basis.
| What can be read | Primary evidence behind it | Category |
|---|---|---|
| It wants to control not just the culture "vessels" but what goes into the media and reagents (the critical raw materials) | A run of acquisitions and investments in raw-material makers: Albumedix (recombinant albumin), CellGenix (cytokines and growth factors), Polyplus (transfection reagents) and Nanotein (activation reagents). Capacity expansion in Freiburg and Illkirch | Inference |
| In cell therapy it is moving from supplying components to supplying "the entire manufacturing system" | The Eveo release quotes an executive board member on "combining raw materials, production equipment, software and QC assays into a scalable system" | Inference |
| It will not become a CDMO itself, but will spread its equipment through CDMOs | Eveo was piloted with ElevateBio (a CDMO), which will use one of the first systems for its customers. The annual report makes no mention of contract manufacturing | Inference |
| It plans to improve margins by raising the share of consumables | The mid-term target release cites "a growing revenue share of high-margin consumables" as a driver of margin expansion, alongside scale effects and operational improvements | Sourced |
| For antibody drugs, it wants the shift to continuous manufacturing to become the industry standard | Pionic, co-developed with Sanofi, and the plan to train more than 1,000 people a year at NIBRT | Inference |
The Eveo release includes a concrete calculation. Because of its multi-parallel configuration, "a single operator can process eight patient batches at once in the same cleanroom space traditionally needed for two batches"; assuming around seven days per batch and 50 production weeks a year, it enables "production of more than 350 doses per year in a footprint that today yields roughly 100 doses" Sourced. This is a statement about the system's performance, but it also means that the amount of media, reagents and bags one system consumes rises roughly fourfold. Because Sartorius owns even the raw materials for those media (albumin and cytokines) and the reagents, wider adoption of the system translates directly into higher sales of its own consumables. Our reading is that the raw-material acquisitions and the launch of Eveo are two halves of the same strategy Not yet confirmed.
9. Map of cell culture partnerships
The map shows that most of Sartorius's relationships are acquisitions and investments rather than co-development. What is more, most of the companies it has bought are not equipment makers but makers of media raw materials and reagents Sourced. The partners that do appear, a CDMO (ElevateBio) and a large drug maker (Sanofi), are both partners in developing or testing its own equipment.
10. Technologies, products and services
| Area | Main products and services (as described in the annual report and releases) | (1) Biologics / (2) Cell therapy |
|---|---|---|
| Cell lines and media | Cell lines, media and reagents. Powder media made in Yauco, Puerto Rico. Also a media plant in Beit Haemek, Israel | (1) (2) |
| Critical media raw materials | Recombinant human albumin (formerly Albumedix), and cytokines and growth factors (formerly CellGenix, Freiburg) | Mainly (2) |
| Gene delivery | Transfection reagents and plasmid DNA (formerly Polyplus, Illkirch) | (2) (viral vectors) |
| Bioreactors and fluid management | Bioreactors, and single-use bags, tubing and connectors (with Aubagne as the main site) | (1) (2) |
| Separation and purification | Filtration (Sartopore EVO, a PFAS-free sterile filter; Sartocon Hydrosart) and chromatography | (1) |
| Continuous manufacturing and digital | Pionic (a continuous manufacturing platform co-developed with Sanofi) and Biobrain Operate (a cloud-based automation and process management application) | (1) |
| Cell therapy manufacturing systems | Eveo (integrates cell selection, activation, genetic modification, expansion, wash and concentration, and formulation in a closed system, including QC testing). Exclusive distribution of Nanotein's T cell and NK cell activation reagents | (2) |
| Cell models for research | 3D microtissue models and primary cells (formerly MatTek, in the Lab Products & Services division) | Drug discovery research (not production) |
The Albumedix acquisition announcement describes recombinant human albumin as used "as an animal-free additive to cell culture media and for the stabilization of vaccines and viral therapies". The business was founded in 1984 and had more than 100 employees at the time of the acquisition Sourced.
Albumin is the main component of serum; in media it carries other components and protects cells from physical stress. Serum and albumin derived from human plasma bring lot-to-lot variation and the risk of contamination with infectious agents, so in applications such as cell therapy, where cells go straight back into patients, there is a shift towards materials of constant composition that are not animal-derived. In materials engineering terms, it is the same idea as replacing a natural filler with a synthetic one to stabilise quality. Our reading is that by owning this "replacement material" itself, Sartorius aims to gain an edge in designing chemically defined media Not yet confirmed. Our explainer on cell culture media also covers the move to serum-free media.
11. The risks this company carries
| Risk | Substance | Category |
|---|---|---|
| Large swings in demand | Divisional revenue fell about 19.5%, from €3,326.5 million in 2022 to €2,678.2 million in 2023, and in 2025 had still not returned to its 2022 level | Our calculation |
| Weak equipment demand | In 2025 industry-wide investment restraint cut sales of equipment and systems. In the first half of 2026 they had only just returned to slight growth | Sourced |
| Debt from acquisitions | Net debt of €3,741.1 million, 3.55 times underlying EBITDA (end of 2025). Bridge financing for the Polyplus acquisition was refinanced with bonds | Sourced |
| Tariffs | A 15% U.S. tariff on most imports from the EU. In the first half of 2026 the company received refunds of tariffs ruled unlawful and deducted about €26 million of expected customer refunds from revenue | Sourced |
| Reliance on a particular site | Some products are made only at the media plant in Israel, and backup capacity is being built (products from that plant account for less than 1% of revenue) | Sourced |
| Customer concentration | The 50 largest customers account for almost half of revenue. No single customer contributes more than 5% | Sourced |
| No track record for Eveo yet | Orders open in September 2026 and first deliveries are expected in 2027. The cost saving of around 90% is an estimate from financial modelling | Not yet confirmed |
| Minority shareholders in the subsidiary | About 28.5% of Sartorius Stedim Biotech is held by outside shareholders; profit attributable to non-controlling interests was €75.5 million in 2025 | Sourced |
12. Glossary
- Bioprocess Solutions
- One of Sartorius's divisions, covering equipment and consumables for developing and manufacturing biopharmaceuticals. 81% of 2025 revenue.
- Culture media
- The liquids (or powders dissolved before use) that nourish cells. See our explainer on cell culture media for more.
- Recombinant human albumin
- Human albumin made by genetic engineering. Used in place of serum-derived products as a media additive or stabiliser.
- Cytokines and growth factors
- Proteins that promote cell growth and differentiation. Essential raw materials for culturing cells for therapy.
- Transfection reagent
- A reagent that gets DNA taken up into cells. Used in viral vector manufacturing.
- Single-use systems
- An approach using disposable bags and fluid paths for culture and liquid transfer. See also our explainer on single-use systems.
- Continuous manufacturing
- Making a drug by running culture and purification without stopping. Traditionally, batch manufacturing in fixed lots has been the norm.
- CAR-T cell therapy
- A treatment in which a patient's T cells are genetically modified to attack cancer. See our explainer on CAR-T cells for more.
- Underlying EBITDA
- Earnings before interest, taxes, depreciation and amortisation, excluding extraordinary items. Sartorius's main measure of profitability.
- Constant currencies (cc)
- Growth calculated at the previous year's exchange rates. A measure of underlying performance excluding currency movements.
13. References
- Sartorius AG Annual Report 2025 (published February 2026). Key figures, divisional results, business model, vertical integration, R&D costs, capital expenditure, employees, competitors, the stake in Sartorius Stedim Biotech, MatTek and Nanotein, the 2026 forecast, and risks (the Israeli site, tariffs, customer concentration). https://www.sartorius.com/download/1796536/fy-2025-download-annual-report-sag-en-data.pdf
- Sartorius AG Half-Year Report January to June 2026. Divisional revenue for the first half of 2026, the effect of tariff refunds, the confirmed full-year forecast and headcount. https://www.sartorius.com/download/1845862/h1-2026-download-half-year-report-sag-en-data.pdf
- Sartorius AG Media release, "Sartorius launches next-generation platform to boost efficiency in cell therapy production" (16 March 2026). Eveo. https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-launches-next-generation-platform-to-boost-efficiency-in-cell-therapy-production-1806254
- Sartorius AG Media release, "Sartorius sharpens strategy with biopharma focus and sets new mid-term growth targets" (17 March 2026). https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-sharpens-strategy-with-biopharma-focus-and-sets-new-mid-term-growth-targets-1807002
- Sartorius AG Media release, "Sartorius opens new competence center for cell and gene therapy components in Freiburg, Germany" (21 May 2026). https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-opens-new-competence-center-for-cell-and-gene-therapy-components-in-freiburg-germany-1827390
- Sartorius AG Media release, "Sartorius expands production of key components for cell and gene therapies in France" (18 September 2025). https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-expands-production-of-key-components-for-cell-and-gene-therapies-in-france-1747896
- Sartorius Stedim Biotech Media release, "Sartorius Stedim Biotech and Nanotein Technologies partner to advance cell therapy manufacturing" (11 August 2025). https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-and-nanotein-technologies-partner-to-advance-cell-therapy-manufacturing-1740194
- Sartorius AG Media release, "Sartorius to acquire microtissue business MatTek from Swedish BICO AB" (4 April 2025). https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-to-acquire-microtissue-business-mattek-from-swedish-bico-ab-1678424
- Sartorius AG Media release, "Sartorius completes acquisition of MatTek" (1 July 2025). https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-completes-acquisition-of-mattek-1701286
- Sartorius AG Media release, "Sartorius to acquire Polyplus" (31 March 2023). https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-to-acquire-polyplus-1410674
- Sartorius AG Media release, "Sartorius completes acquisition of Polyplus" (18 July 2023). https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-completes-acquisition-of-polyplus-1454004
- Sartorius AG Media release, "Sartorius to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions" (8 August 2022). https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-to-acquire-albumedix-strengthening-portfolio-of-innovative-advanced-therapy-solutions-1281024
- Sartorius AG Media release, "Sartorius opens manufacturing facility for cell culture media in Puerto Rico" (18 July 2023). https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-opens-manufacturing-facility-for-cell-culture-media-in-puerto-rico-1451978
- Sartorius AG Media release, "Extended collaboration with Sartorius powers new biomanufacturing lab at McMaster University, Canada" (21 January 2025). https://www.sartorius.com/en/company/newsroom/corporate-news/extended-collaboration-with-sartorius-powers-new-biomanufacturing-lab-at-mcmaster-university-canada-1663078
- Sartorius AG Media release, "Sartorius and NIBRT announce partnership: Pioneering dedicated training center for intensified and continuous bioprocessing" (16 September 2026). https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-and-nibrt-announce-partnership-pioneering-dedicated-training-center-for-intensified-and-continuous-bioprocessing-1780348
- Sartorius AG Media release, "Sartorius agrees with BICO on strategic cooperation as well as a 10 percent capital investment" (8 December 2022). https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-agrees-with-bico-on-strategic-cooperation-as-well-as-a-10-percent-capital-investment-1343948
- Sartorius AG Official website (source of the logo image). https://www.sartorius.com/en
14. Claim-to-source audit
| Claim in the article | Category | Source |
|---|---|---|
| Legal name, founded 1870, head office in Göttingen, MDAX and TecDAX, more than 30 manufacturing sites, 71.5% stake in Sartorius Stedim Biotech | Sourced | Reference 1 https://www.sartorius.com/download/1796536/fy-2025-download-annual-report-sag-en-data.pdf |
| Group revenue, R&D costs, capital expenditure and headcount (2023 to 2025) | Sourced | Reference 1 https://www.sartorius.com/download/1796536/fy-2025-download-annual-report-sag-en-data.pdf |
| Bioprocess Solutions revenue, underlying EBITDA and headcount (2022 to 2025), its 81% share, the regional mix, the drivers of growth and the decline in equipment | Sourced | Reference 1 https://www.sartorius.com/download/1796536/fy-2025-download-annual-report-sag-en-data.pdf |
| The division's customers and products, single-use products at just above three-quarters of revenue, and Danaher, Merck KGaA and Thermo Fisher named as competitors | Sourced | Reference 1 https://www.sartorius.com/download/1796536/fy-2025-download-annual-report-sag-en-data.pdf |
| Divisional revenue in the first half of 2026, the effect of tariff refunds and the confirmed full-year forecast | Sourced | Reference 2 https://www.sartorius.com/download/1845862/h1-2026-download-half-year-report-sag-en-data.pdf |
| The fall of about 19.5% from 2022 to 2023, and the Polyplus price at about 80% of divisional revenue | Our calculation | Calculated by this article from figures in References 1 and 10 |
| Vertical integration (making products from films and polymers in house) and ISCC PLUS certification | Sourced | Reference 1 https://www.sartorius.com/download/1796536/fy-2025-download-annual-report-sag-en-data.pdf |
| Eveo's functions, the ElevateBio pilot, eight batches at once, more than 350 doses a year, the estimated cost saving of around 90%, orders from September 2026 and deliveries in 2027 | Sourced | Reference 3 https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-launches-next-generation-platform-to-boost-efficiency-in-cell-therapy-production-1806254 |
| Mid-term targets (divisional growth of 9% to 12% a year from 2027, margin improvement), the list of emerging businesses, and the company's market growth assumption | Sourced | Reference 4 https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-sharpens-strategy-with-biopharma-focus-and-sets-new-mid-term-growth-targets-1807002 |
| The new Freiburg site (more than €140 million, about 140 staff and up to 180, the history of CellGenix) | Sourced | Reference 5 https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-opens-new-competence-center-for-cell-and-gene-therapy-components-in-freiburg-germany-1827390 |
| The GMP transfection reagent plant in Illkirch | Sourced | Reference 6 https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-expands-production-of-key-components-for-cell-and-gene-therapies-in-france-1747896 |
| Minority stake of up to US$3 million in Nanotein and exclusive distribution | Sourced | Reference 7 https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-stedim-biotech-and-nanotein-technologies-partner-to-advance-cell-therapy-manufacturing-1740194 |
| The MatTek acquisition (US$80 million, more than 80 staff) | Sourced | Reference 8 https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-to-acquire-microtissue-business-mattek-from-swedish-bico-ab-1678424 |
| Completion of the MatTek acquisition (1 July 2025) and integration into the Lab Products & Services division | Sourced | Reference 9 https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-completes-acquisition-of-mattek-1701286 |
| Agreement to acquire Polyplus (about €2.4 billion, about 270 staff, via Sartorius Stedim Biotech) | Sourced | Reference 10 https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-to-acquire-polyplus-1410674 |
| Completion of the Polyplus acquisition (18 July 2023) | Sourced | Reference 11 https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-completes-acquisition-of-polyplus-1454004 |
| The Albumedix acquisition (about £415 million, uses of recombinant albumin, founded 1984, more than 100 staff) | Sourced | Reference 12 https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-to-acquire-albumedix-strengthening-portfolio-of-innovative-advanced-therapy-solutions-1281024 |
| The media plant in Yauco, Puerto Rico (21,500 square feet) | Sourced | Reference 13 https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-opens-manufacturing-facility-for-cell-culture-media-in-puerto-rico-1451978 |
| The bioprocess automation lab at McMaster University | Sourced | Reference 14 https://www.sartorius.com/en/company/newsroom/corporate-news/extended-collaboration-with-sartorius-powers-new-biomanufacturing-lab-at-mcmaster-university-canada-1663078 |
| The continuous manufacturing training centre with NIBRT (more than 1,000 people a year) | Sourced | Reference 15 https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-and-nibrt-announce-partnership-pioneering-dedicated-training-center-for-intensified-and-continuous-bioprocessing-1780348 |
| The partnership with BICO and the stake of about 10.1% (about €45 million) | Sourced | Reference 16 https://www.sartorius.com/en/company/newsroom/corporate-news/sartorius-agrees-with-bico-on-strategic-cooperation-as-well-as-a-10-percent-capital-investment-1343948 |
| Net debt and leverage, tariffs, the Israeli site, customer concentration and non-controlling interests | Sourced | Reference 1 https://www.sartorius.com/download/1796536/fy-2025-download-annual-report-sag-en-data.pdf |
| The three types of cell culture company, and placing Sartorius among the suppliers | Our calculation | Our own classification. Companies shown are examples from the 20 in this series |
| Revenue from media and cell therapy products, Eveo's price and order targets, Polyplus's revenue since the acquisition, media production capacity, and the CellGenix price | Not yet confirmed | Not in References 1 to 5. This article makes no estimate https://www.sartorius.com/download/1796536/fy-2025-download-annual-report-sag-en-data.pdf |
| The readings about controlling critical raw materials, moving to supplying the whole manufacturing system, spreading equipment through CDMOs, and standardising continuous manufacturing | Inference | This article's interpretation of statements in References 1, 3, 5, 7, 10, 12 and 15 |
| The materials significance of making wetted films in house and of replacement with recombinant albumin | Not yet confirmed | This article's commentary on the facts in References 1 and 12 |
Last updated 24 September 2026 / Troy Technical
The figures in this article are based on Sartorius AG's annual report, half-year report and official media releases. No research-firm estimates or press-based figures have been used (including the research-firm market estimate quoted in the annual report). Passages marked "Inference" are this article's interpretation of primary sources, not statements made by the company.